311 related articles for article (PubMed ID: 21251686)
21. Baseline serum concentrations of TRAIL in early rheumatoid arthritis: relationship with response to disease-modifying antirheumatic drugs.
Secchiero P; Corallini F; Castellino G; Bortoluzzi A; Caruso L; Bugatti S; Bosco R; Montecucco M; Trotta F
J Rheumatol; 2010 Jul; 37(7):1461-6. PubMed ID: 20472926
[TBL] [Abstract][Full Text] [Related]
22. Urinary albumin excretion rate and its determinants after 6 years in non-insulin-dependent diabetic patients.
Wirta OR; Pasternack AI; Mustonen JT; Koivula TA; Harmoinen A
Nephrol Dial Transplant; 1996 Mar; 11(3):449-56. PubMed ID: 8671814
[TBL] [Abstract][Full Text] [Related]
23. Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis.
Harada M; Osuga Y; Hirata T; Hirota Y; Koga K; Yoshino O; Morimoto C; Fujiwara T; Momoeda M; Yano T; Tsutsumi O; Taketani Y
Hum Reprod; 2004 Oct; 19(10):2188-91. PubMed ID: 15242994
[TBL] [Abstract][Full Text] [Related]
24. Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy.
Terekeci HM; Senol MG; Top C; Sahan B; Celik S; Sayan O; Kucukardali Y; Ipcioglu O; Cagiltay E; Oktenli C; Ozata M
Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):119-23. PubMed ID: 19053023
[TBL] [Abstract][Full Text] [Related]
25. Osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as prognostic factors in rheumatoid arthritis: results from the ESPOIR cohort.
Audo R; Daien C; Papon L; Lukas C; Vittecoq O; Hahne M; Combe B; Morel J
Arthritis Res Ther; 2015 Jul; 17(1):193. PubMed ID: 26220665
[TBL] [Abstract][Full Text] [Related]
26. Is there any role for tumour necrosis factor related apoptosis inducing ligand-osteoprotegerin (TRAIL-OPG) interaction in rheumatoid arthritis?
Castellino G; Corallini F; Trotta F; Secchiero P
Ann Rheum Dis; 2008 Aug; 67(8):1196-7. PubMed ID: 18621972
[No Abstract] [Full Text] [Related]
27. Association of haptoglobin phenotypes with markers of diabetic nephropathy in Type 2 diabetes mellitus.
Awadallah SM; Saleh SA; Abu Shaqra QM; Hilow H
J Diabetes Complications; 2008; 22(6):384-8. PubMed ID: 18413152
[TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor-related apoptosis-inducing ligand and vascular calcification.
Chasseraud M; Liabeuf S; Mozar A; Mentaverri R; Brazier M; Massy ZA; Kamel S
Ther Apher Dial; 2011 Apr; 15(2):140-6. PubMed ID: 21426505
[TBL] [Abstract][Full Text] [Related]
29. Possible role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand as markers of plaque instability in coronary artery disease.
Shaker OG; El-Shehaby A; Nabih M
Angiology; 2010 Nov; 61(8):756-62. PubMed ID: 20498140
[TBL] [Abstract][Full Text] [Related]
30. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes.
Saraheimo M; Forsblom C; Thorn L; Wadén J; Rosengård-Bärlund M; Heikkilä O; Hietala K; Gordin D; Frystyk J; Flyvbjerg A; Groop PH;
Diabetes Care; 2008 Jun; 31(6):1165-9. PubMed ID: 18346990
[TBL] [Abstract][Full Text] [Related]
31. Serum Angptl2 levels are independently associated with albuminuria in type 2 diabetes.
Li Q; Gong W; Yang Z; Lu B; Yang Y; Zhao W; Hu R
Diabetes Res Clin Pract; 2013 Jun; 100(3):385-90. PubMed ID: 23602322
[TBL] [Abstract][Full Text] [Related]
32. Increased serum levels of interleukin-18 in patients with diabetic nephropathy.
Mahmoud RA; el-Ezz SA; Hegazy AS
Ital J Biochem; 2004 Jul; 53(2):73-81. PubMed ID: 15646011
[TBL] [Abstract][Full Text] [Related]
33. Does osteoprotegerin relate to micro- and macrovascular complications in long-term type 1 diabetes?
Grauslund J; Rasmussen LM; Green A; Sjølie AK
Scand J Clin Lab Invest; 2010 Apr; 70(3):188-93. PubMed ID: 20205614
[TBL] [Abstract][Full Text] [Related]
34. Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure.
Kuźniewski M; Fedak D; Dumnicka P; Stępień E; Kuśnierz-Cabala B; Cwynar M; Sułowicz W
Adv Med Sci; 2016 Sep; 61(2):269-275. PubMed ID: 27128817
[TBL] [Abstract][Full Text] [Related]
35. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
36. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients.
Xiang GD; Sun HL; Zhao LS
Diabetes Res Clin Pract; 2007 May; 76(2):199-206. PubMed ID: 17023086
[TBL] [Abstract][Full Text] [Related]
37. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?
Chico A; Pérez A; Córdoba A; Arcelús R; Carreras G; de Leiva A; González-Sastre F; Blanco-Vaca F
Diabetologia; 1998 Jun; 41(6):684-93. PubMed ID: 9662051
[TBL] [Abstract][Full Text] [Related]
38. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Patiño-García A; Zalacain M; Folio C; Zandueta C; Sierrasesúmaga L; San Julián M; Toledo G; De Las Rivas J; Lecanda F
Clin Cancer Res; 2009 Aug; 15(16):5082-91. PubMed ID: 19671856
[TBL] [Abstract][Full Text] [Related]
39. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria.
Nellemann B; Gormsen LC; Dollerup J; Schmitz O; Mogensen CE; Rasmussen LM; Nielsen S
Diabetes Care; 2007 Dec; 30(12):3122-4. PubMed ID: 17804683
[No Abstract] [Full Text] [Related]
40. The plasma osteoprotegerin level and osteoprotegerin expression in renal biopsy tissue are increased in type 2 diabetes with nephropathy.
Wang ST; Zhang CY; Zhang CM; Rong W
Exp Clin Endocrinol Diabetes; 2015 Feb; 123(2):106-11. PubMed ID: 25502845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
